share_log

Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $30

Benzinga ·  Apr 25 08:53

Piper Sandler analyst Joseph Catanzaro maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $26 to $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment